Compelling clinical evidence establishes that buprenorphine is similar to methadone in
efficacy for opiate detoxification and maintenance but safer than methadone in an overdose …

Buprenorphine is a new and attractive medication option for many opioid-addicted adults
and their physicians. Before initiating buprenorphine treatment, providers must be aware of …

Objectives This study compared 24‐, 48‐, 72‐, and 96‐hour buprenorphine dosing
regimens in opioid‐dependent outpatients. Methods Fourteen subjects received …

We describe a sensitive and specific method for the measurement of buprenorphine in
human plasma. The method involves a structural analog as an internal calibrator, careful …

Sublingual buprenorphine is a promising new treatment for opiate dependence, but its
opioid agonist effects pose a risk for parenteral abuse. A formulation combining …

Objectives: Buprenorphine at high dosage became available in France in 1996, as a
substitution treatment for heroin addicts. Since this date, numerous deaths were attributed to …

Eighty-five heroin addicts who were unwilling to receive methadone maintenance or enter
therapeutic communities were assessed, single-blind, for the lowest sublingual dose of …

A liquid chromatographic-electrospray ionization-tandem mass spectrometric method has
been developed and validated for determination of the antiabuse medication …

Rationale: Buprenorphine is a partial mu opioid agonist under development as a sublingual
(SL) medication for opioid dependence treatment in the United States. Because …

Buprenorphine/naloxone (Suboxone®) comprises the partial μ-opioid receptor agonist
buprenorphine in combination with the opioid antagonist naloxone in a 4: 1 ratio. When …